Thin-film nanocomposite NF membrane with GO on macroporous hollow fiber ceramic substrate for efficient heavy metals removal.

The ceramic membrane has been widely used in the wastewater treatment based on the chemical resistance and superior separation performance. A robust and defect-free thin-film nanocomposite (TFN) nanofiltration (NF) membrane on the macroporous hollow fiber ceramic (HFC) substrate was novelly developed for heavy metals removal. Before interfacial polymerization (IP), the aqueous solution of graphene oxide (GO) grafted with ethylenediamine (EDA) was deposited on the HFC substrate by vacuum filtration. Then, a thin polyamide (PA) film was fabricated by EDA and 1,3,5-trimesoyl chloride (TMC), followed by heat treatment. The effects of GO content and EDA concentration on the performance of the NF membrane have been systematically investigated. The results showed that when the GO content was 0.015 mg·mL-1 and the EDA concentration was 0.75 wt.%, the as-prepared eGO3/PA-HFC membrane had a rejection rate of 94.12% for MgCl2 and a pure water flux of 18.03 L·m-2·h-1. Additionally, the removal ability of eGO3/PA-HFC membranes for heavy metal ions was satisfactory (93.33%, 92.73%, 90.45% and 88.35% for Zn2+, Cu2+, Ni2+ and Pb2+, respectively). The study explored further that it was efficient and stable for heavy metal ions removal during 30 h in the simulated tap water and mining wastewater, which indicated that the eGO/PA-HFC membrane has great application potential in wastewater treatment.

Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA.

[This corrects the article DOI: 10.3389/fbioe.2020.00512.].

Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA.

As a gene therapy strategy, RNA interference (RNAi) offers tremendous tumor therapy potential. However, its therapeutic efficacy is restricted by its inferior ability for targeted delivery and cellular uptake of small interfering RNA (siRNA). This study sought to develop a dual-ligand nanoparticle (NP) system loaded with siRNA to promote targeted delivery and therapeutic efficacy. We synthesized a dual receptor-targeted chitosan nanosystem (GCGA), whose target function was controlled by the ligands of galactose of lactobionic acid (LA) and glycyrrhetinic acid (GA). By loading siPAK1, an siRNA targeting P21-activated kinase 1 (PAK1), a molecular-targeted therapeutic dual-ligand NP (GCGA-siPAK1) was established. We investigated the synergistic effect of these two targeting units in hepatocellular carcinoma (HCC). In particular, GCGA-siPAK1 enhanced the NP targeting ability and promoted siPAK1 cell uptake. Subsequently, dramatic decreases in cell proliferation, invasion, and migration, with an apparent increase in cell apoptosis, were observed in treated cells. Furthermore, this dual-ligand NP gene delivery system demonstrated significant anti-tumor effects in tumor-bearing mice. Finally, we illuminated the molecular mechanism, whereby GCGA-siPAK1 promotes endogenous cell apoptosis through the PAK1/MEK/ERK pathway. Thus, the dual-target property effectively promotes the HCC therapeutic effect and provides a promising gene therapy strategy for clinical applications.